Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results
View ORCID ProfileRu Han, Clément François, Mondher Toumi
doi: https://doi.org/10.1101/2020.06.22.20135434
Ru Han
1University of Aix-Marseille, Marseille, France
2Creativ-Ceutical, Paris, France
Clément François
1University of Aix-Marseille, Marseille, France
2Creativ-Ceutical, Paris, France
Mondher Toumi
1University of Aix-Marseille, Marseille, France
2Creativ-Ceutical, Paris, France
Posted June 23, 2020.
Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results
Ru Han, Clément François, Mondher Toumi
medRxiv 2020.06.22.20135434; doi: https://doi.org/10.1101/2020.06.22.20135434
Subject Area
Subject Areas
- Addiction Medicine (357)
- Allergy and Immunology (681)
- Anesthesia (182)
- Cardiovascular Medicine (2694)
- Dermatology (229)
- Emergency Medicine (405)
- Epidemiology (12333)
- Forensic Medicine (10)
- Gastroenterology (773)
- Genetic and Genomic Medicine (4170)
- Geriatric Medicine (393)
- Health Economics (689)
- Health Informatics (2703)
- Health Policy (1010)
- Hematology (366)
- HIV/AIDS (864)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (446)
- Neurology (3954)
- Nursing (214)
- Nutrition (587)
- Oncology (2084)
- Ophthalmology (596)
- Orthopedics (245)
- Otolaryngology (308)
- Pain Medicine (254)
- Palliative Medicine (75)
- Pathology (474)
- Pediatrics (1134)
- Primary Care Research (462)
- Public and Global Health (6593)
- Radiology and Imaging (1430)
- Respiratory Medicine (879)
- Rheumatology (416)
- Sports Medicine (345)
- Surgery (456)
- Toxicology (56)
- Transplantation (191)
- Urology (170)